Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $23.52M (cash outflow) rose 15.8% year over year, behind the +21.4% change in trailing-twelve-month net income. Sequentially, it rose 13.2% from the prior quarter. Over 3 fiscal years it compounded at +12.6% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$68.08M (-18.8%) for the fiscal year ending Dec 2026, a slowdown from the +28.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.52M+13.2% QoQ
Last fiscal yearDec 2025
-$83.87M+28.3% YoY
LTMMar 2026
-$87.07M+21.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.8%+15.9%+0.1 pp
1 year+28.3%-18.8%-47.1 pp
3-year CAGR+12.6%-24.9%-37.5 pp
5-year CAGR-47.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(83.87M) USD
Year-over-year change
-28.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ARTV compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +21.4% is the 3rd highest of 9, against a peer median of -18.6%.
  • Over three fiscal years its annual growth of +12.6% compares with a peer median of -11.5%.
ARTV Competitors
Net Income for ARTV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$153.6M USD-37.4%+17.0%154.2%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$124.13M USD-44.6%-16.7%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$108M USD+21.2%+44.8%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$88.87M USD-31.7%-6.3%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$87.07M USD+21.4%+12.6%—
CNTBConnect Biopharma Holdings LimitedFY2025$55.48M USD+255.0%-21.8%86687.5%
STTKShattuck Labs, Inc.LTM Mar 2026$49.87M USD-29.4%-21.8%4987.4%
DTILPrecision BioSciences, Inc.LTM Mar 2026$43.6M USD+98.3%-25.7%96.7%
IFRXInflaRx N.V.LTM Mar 2026€41.2M EUR-7.9%+14.1%140477.1%
Peer median (excluding ARTV) —-18.6%-11.5%4987.4%

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.83M)(58.79M)(28.72M)(65.37M)(83.87M)
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
Deferred Income Tax00000
Stock-Based Compensation4.31M6.58M7.05M6.98M6.82M
Change in Working Capital33.41M(3.87M)(28.28M)(325K)(424K)
Accounts Receivables(468K)(57K)(1.23M)1.61M79K
Inventory00000
Accounts Payables(1.24M)190K(408K)519K(760K)
Other Working Capital35.13M(4M)(26.64M)(2.46M)257K
Other Non-Cash Items18.55M4.08M251K1.26M(1.88M)
Operating Cash Flow(15.3M)(50.83M)(47.43M)(55.03M)(76.75M)
Capital Expenditures(1.72M)(6.3M)(3.26M)(642K)(2.59M)
Acquisitions (Net)00000
Purchases of Investments00(49.52M)(176.17M)(44.88M)
Sales of Investments0026.8M56.35M110.87M
Other Investing Activities00000
Investing Cash Flow(1.72M)(6.3M)(25.98M)(120.46M)63.41M
Debt Repayment000(149K)(132K)
Common Stock Issued000166.51M371K
Common Stock Repurchased0(5K)(12K)(4.18M)0
Dividends Paid00000
Other Financing Activities(1.86M)(1.26M)24.4M51K(230K)
Financing Cash Flow152.75M(1.26M)24.39M162.23M9K
Effect of Forex Changes00000
Net Change in Cash135.73M(58.39M)(49.01M)(13.27M)(13.33M)
Free Cash Flow(17.03M)(57.13M)(50.69M)(55.67M)(79.34M)

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.